Viva Biotech HoldingsFRA:VB0 +6.20%43 ROC (Joel Greenblatt) % is 16.64% as of Dec. 2025, which is 34% below its 10-year median of 25.33. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,320 Biotechnology companies, Viva Biotech Holdings ranks better than 86.89% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Viva Biotech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 16.64%.
The historical rank and industry rank for Viva Biotech Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:VB0'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41.48 Med: 25.33 Max: 194.52
Current: 18.51
During the past 10 years, Viva Biotech Holdings's highest ROC (Joel Greenblatt) % was 194.52%. The lowest was -41.48%. And the median was 25.33%.
FRA:VB0's ROC (Joel Greenblatt) % is ranked better than 86.89% of 1320
companies
in the Biotechnology industry
Industry Median: -294.23
vs FRA:VB0: 18.51
Viva Biotech Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Viva Biotech Holdings ROC (Joel Greenblatt) % Related Terms
Viva Biotech Holdings ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 16.64% mean?
Viva Biotech Holdings (FRA:VB0) has a ROC (Joel Greenblatt) % of 16.64% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Viva Biotech Holdings and its competitors. This is 34% below median its historical median of 25.33. According to the industry distribution chart, Viva Biotech Holdings ranks #173 out of 1320 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Viva Biotech Holdings' ROC (Joel Greenblatt) % too high?
Viva Biotech Holdings' current ROC (Joel Greenblatt) % of 16.64% is 34% below median its 10-year median of 25.33. Based on the distribution chart, Viva Biotech Holdings ranks #173 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #173 out of 1320 companies for ROC (Joel Greenblatt) %. This places Viva Biotech Holdings in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current ROC (Joel Greenblatt) % is 16.64%, which is 34% below median its own 10-year median of 25.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.14 — trading 71.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 16.64%, which is 34% below median its 10-year median of 25.33. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current ROC (Joel Greenblatt) % is 16.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.14 is trading 71.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
ROC (Joel Greenblatt) %: 16.64% (34% below median its 10-year median of 25.33)
GF Value™: €0.08 vs. price of €0.14 (71.3% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
